Mild to moderate essential hypertension
Conditions
Interventions
Group A:Allisartan 80mg, orally taken once daily for 8 weeks
Group B:Allisartan 160mg, orally taken once daily for 8 week
Group C:Allisartan 240mg, orally taken once daily for 8 weeks
Group D:losartan 50mg, orally taken once daily for 8 weeks
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 70 years old; 2. 18.5kg/m2 <= BMI <= 30kg/m2 (BMI= body weight/height2); 3. Mild to moderate essential hypertension according to the diagnostic criteria of China (2005); 4. The mean seated blood pressure after 2-week washout period with placebo (the blood pressure should be detected 3 times every 2 minutes after 5-minute resting in sitting position and then take the mean value) should be 140mmHg <= SBP<180mmHg and 90mmHg <= DBP< 110mmHg; 5. To be able to and willing to provide signed consent.
Exclusion criteria
Exclusion criteria: 1. Having been diagnosed or suspected as secondary hypertension; 2. Differece of SeSBP>20mmHg or difference of SeDBP>10mmHg ad tres vices when determined; 3. Sick sinus syndrome, II~III atrial ventricular block, atrial flutter, atrial fibrillation, or other malignant arrhythmia; 4. Aneurysm in conducting artery or dissecting aneurysm, percutaneous tranluminal coronary angioplasty (PTCA) or other cardiac surgery; 5. Unstable angina pectoris, acute myocardial infarction, cardiac failure, and cerebral accidents within recent 6 months; 6. Asthma or moderate to severe chronic obstructive lung disease; 7. Uncontrolled diabetes, FBG >=11mmol/L or with complications (degenerative nephritis and peripheral neuropathy); 8. Renal arterial stenosis; 9. Renal inadequacy (Cr>1.5*ULN (the upper limit of the normal range)); 10. Serious hepatopathy or hepatic inadequacy (ALT, AST or TBIL> 2*ULN); 11. Electrolyte disturbances (blood potassium or sodium abnormality); 12. Subjects with lower blood volume; 13. Female subjects with pregnancy or in lactation; 14. Subjects with drug or alcohol dependence; 15. Concomitant treatment with other drugs which will affect the blood pressure; 16. History of drug allergy or known allergy to ARB drugs; 17. Having participated in other drug's clinical study within recent 3 months; 18. Suspected as white overcoat hypertension according to the judgement of investigators; 19. Subjects are thought unsuitable for the study by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change value of seated blood pressure at Weeks 8 compared to baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| the change value of seated blood pressure at Weeks 4 compared to baseline;the change value of seated blood pressure at Week 4 and Week 8 compared to baseline in subjects wh;the percentage of subjects whose seated blood pressure is normalized at Week 4 and Week 8; | — |
Countries
China
Contacts
Public ContactNinglin Sun
Peking University People's Hospital
Outcome results
None listed